Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0420
Source ID: NCT00641589
Associated Drug: Epoetin Alfa
Title: A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Chronic Kidney Disease|Anemia
Interventions: DRUG: epoetin alfa
Outcome Measures: Primary: The primary objective of the study is to describe the pharmacokinetic (PK) profiles of 4 different dosing regimens of PROCRIT in patients with anemia secondary to chronic kidney disease (CKD) not on dialysis. | Secondary: The secondary objective is to describe the pharmacodynamic (PD) response to the four PROCRIT study dosing regimens using the following outcomes: absolute and % reticulocyte count, hemoglobin (Hb), hematocrit (Hct), and red blood cell (RBC) count.
Sponsor/Collaborators: Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Collaborators: Centocor Ortho Biotech Services, L.L.C.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 40
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2006-01
Completion Date: 2006-11
Results First Posted:
Last Update Posted: 2011-05-18
Locations:
URL: https://clinicaltrials.gov/show/NCT00641589